Markets have rebounded, and volatility has settled. That's very good news for the IPO market, which is especially impacted by market turmoil. Right now we're in the annual February lull, and companies are putting off IPOs to finalize full 2017 financials...read more
Biofrontera, which sells treatments for skin conditions caused by sun damage, raised $12 million by offering 1.2 million ADSs at $9.88. Biofrontera plans to list on the Nasdaq under the symbol BFRA. The Benchmark Company acted as a lead manager on the deal....read more
Three small deals are scheduled for the week ahead, two of which are hold-overs from last week. We expect IPO activity to remain muted until late February, driven by a combination of the upcoming President's Day holiday and companies getting in full...read more
Biofrontera, which sells treatments for skin conditions caused by sun damage, increased the proposed price range for its upcoming US IPO on Wednesday. The Leverkusen, Germany-based company now plans to raise up to $36 million by offering 3 million ADSs at a...read more
US IPO Weekly Recap: IPO market recovers in a week with 4 small deals
Markets have rebounded, and volatility has settled. That's very good news for the IPO market, which is especially impacted by market turmoil. Right now we're in the annual February lull, and companies are putting off IPOs to finalize full 2017 financials...read more
Skincare pharma Biofrontera prices $12 million US IPO at $9.88
Biofrontera, which sells treatments for skin conditions caused by sun damage, raised $12 million by offering 1.2 million ADSs at $9.88. Biofrontera plans to list on the Nasdaq under the symbol BFRA. The Benchmark Company acted as a lead manager on the deal....read more
US IPO Week Ahead: Five minor IPOs expected to price ahead of mid-February lull
Three small deals are scheduled for the week ahead, two of which are hold-overs from last week. We expect IPO activity to remain muted until late February, driven by a combination of the upcoming President's Day holiday and companies getting in full...read more
German dermatology biotech Biofrontera increases range to $11 to $13, now raising up to $36 million
Biofrontera, which sells treatments for skin conditions caused by sun damage, increased the proposed price range for its upcoming US IPO on Wednesday. The Leverkusen, Germany-based company now plans to raise up to $36 million by offering 3 million ADSs at a...read more